connected devices
Ahead of ASCO: Opportunities for A More Modern, Equitable Oncology Enterprise
In the lead-up to ASCO 2024 the oncology enterprise has much to celebrate. New drug approvals at FDA reached a three-decade high with anticancer drugs representing the largest percentage of new approvals. EHR vendors are making proactive commitments to cancer data standards to support scientific breakthroughs and more effective cancer treatment. And, for the first time ever, payers are offering a new reimbursable pathway for improved cancer outcomes via comprehensive supportive care.
No delays: How Medable achieves a 99% device shipment rate
With BBC Research forecasting that “the global smartphone-based patient monitoring market should reach $21.5 billion by 2027,” it’s safe to say that smartphones, tablets, and other devices have become a cornerstone of modern clinical trials.
Today’s trials use smart devices to help facilitate several important trial activities, like informed consent, data collection, patient feedback, and more. As a result, ensuring device delivery logistics has become a crucial step in getting a trial started and keeping participants engaged throughout its duration.
At Medable, we often handle device shipping for our customers' clinical trials. The team responsible for providing this service, led by Carl Franzetti, SVP of Professional Global Services has a market-leading 99% device shipment rate, with the remaining 1% resulting from normal business operation limitations such as weather outages.
The result? Our customer’s trials start on time and their participants are better engaged.